NASDAQ · SCAGW

Scage Future

$0.03 -$0.01 (-24.54%) 1D Market open

Key Metrics

Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow −$5.91M
Beta · 1Y 0.25
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jun 5 high, the share price fell 55%.

    Peak close $0.07 on Jun 5; trough close $0.03 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -55%
  • Jul 24
    The stock moved -24.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 24
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 5
    The stock moved +59.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.03 – $0.14
Avg volume · 20D35.9K
Net cash
Book value / share
ExchangeNASDAQ
About Scage Future
IPO dateJun 30, 2025
Employees99

Scage Future is a zero-emission solution provider in China, focusing on the development and commercialization of heavy-duty new energy vehicle ("NEV") trucks and e-fuel solutions. The company generates revenues principally from sales of commercial NEVs and components.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio0.20
Quick ratio0.16
Debt / equity
Debt / EBITDA
Net cash
Working capital−$20.39M

Cash Flow · TTM

Operating CF −$5.89M
Capex −$13.49K
Free cash flow −$5.91M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings